Lifeboat Foundation

Turning off inflammatory protein extends healthy lifespan in mice.

A protein that promotes inflammation could hold the key to a longer, healthier life.

Humans also have the protein, called IL-11, offering hope for a future longevity treatment.

Continue reading “Mice live longer when inflammation-boosting protein is blocked” »

Large language models trained on religious texts claim to offer spiritual insights on demand. What could go wrong?

By Webb Wright

Just before midnight on the first day of Ramadan last year, Raihan Khan—a 20-year-old Muslim student living in Kolkata—announced in a LinkedIn post that he had launched QuranGPT, an artificial-intelligence-powered chatbot he had designed to answer questions and provide advice based on Islam’s holiest text. Then he went to sleep. He awoke seven hours later to find it had crashed because of an overflow of traffic. A lot of the comments were positive, but others were not. Some were flat-out threatening.

Poe is an animated talking teddy bear toy that uses ChatGPT to generate children’s stories. I took it for an early test run and bedtime got strange.

Lucid says new updates make the Air Pure electric sedan beat Tesla and everybody else when it comes to powertrain efficiency.

According to a report by KPRC and the Texas General Land Office, officials are watching condensate leaking from an offshore drilling platform.

Stunt marks Elton John’s appearance as Glastonbury.

Two companies are coming together to develop an AI Health Coach that uses the power of artificial intelligence to battle chronic diseases.

Large-scale neural network models form the basis of many AI-based technologies such as neuromorphic chips, which are inspired by the human brain. Training these networks can be tedious, time-consuming, and energy-inefficient given that the model is often first trained on a computer and then transferred to the chip. This limits the application and efficiency of neuromorphic chips.

TU/e researchers have solved this problem by developing a neuromorphic device capable of on–chiptraining that eliminates the need to transfer trained models to the chip. This could open a route toward efficient and dedicated AI chips.

Have you ever thought about how wonderful your brain really is? It’s a powerful computing machine, but it’s also fast, dynamic, adaptable, and very energy efficient.

Identifying individuals who are at a high risk of age-related morbidities may aid in personalized medicine. Circulating proteins can discriminate disease cases from controls and delineate the risk of incident diagnoses^{1,2,3,4,5,6,7,8}. While singular protein markers offer insight into the mediators of disease^5,9,10,11, simultaneously harnessing multiple proteins may improve clinical utility¹². Clinically available non-omics scores such as QRISK typically profile the 10-year onset risk of a disease¹³. Proteomic scores have recently been trained on diabetes, cardiovascular and lifestyle traits as outcomes in 16,894 individuals¹⁴. Proteomic and metabolomic scores have also been developed for time-to-event outcomes, including all-cause mortality^{6,15,16,17,18,19,20,21}.

Here, we demonstrate how large-scale proteomic sampling can identify candidate protein targets and facilitate the prediction of leading age-related incident outcomes in mid to later life (see the study design summary in Extended Data Fig. 1). We used 1,468 Olink plasma protein measurements in 47,600 individuals (aged 40–70 years) available as part of the UK Biobank Pharma Proteomics Project (UKB-PPP)²². Cox proportional hazards (PH) models were used to characterize associations between each protein and 24 incident outcomes, ascertained through electronic health data linkage. Next, the dataset was randomly split into training and testing subsets to train proteomic scores (ProteinScores) and assess their utility for modeling either the 5-or 10-year onset of the 19 incident outcomes that had a minimum of 150 cases available. We modeled ProteinScores alongside clinical biomarkers, polygenic risk scores (PRS) and metabolomics measures to investigate how these markers may be used to augment risk stratification.